Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination

Mortality Clinical Trial

Official title:

Diphteria-tetanus-pertussis (DTP) Vaccination and Child Survival: Randomized Study of Not Providing DTP Vaccination Together With or After Measles Vaccination

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00244673
• Other study ID #: CVEK2005-7041-45-DTPMV
• Secondary ID: CVEK2005-7041-45
• Status: Completed
• Phase: Phase 4
• First received: October 25, 2005
• Last updated: February 25, 2012
• Start date: October 2005
• Est. completion date: December 2011

Study information

• Verified date: February 2012
• Source: Bandim Health Project
• Contact: n/a
• Is FDA regulated: No
• Health authority: Guinea-Bissau: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

In non-randomized studies, routine childhood vaccinations have been observed to have non-targeted effects. Difteria-tetanus-pertussis (DTP) vaccine provided with or after measles vaccine (MV) is associated with increased mortality in areas with herd immunity to pertussis.

We will examine in a randomised study of 6000 children the effect of not administering DTP simultaneously with or after MV on overall child mortality, hospitalization rates, and the immunological responses after vaccination. We will also examine potential sex-differential effects in the outcomes and interactions with other vaccines, other health interventions and season.

Description:

Background: Infectious diseases are the main cause of high child mortality in Africa. In several non-randomised studies, routine childhood vaccinations have been observed to have non-targeted effects. Live vaccines like measles vaccine (MV) seem to protect against overall mortality, whereas killed vaccines, like DTP, may have no beneficial effects, especially for girls. DTP provided with or after MV may be associated with increased mortality. The mechanisms behind these effects are unknown.

Hypothesis: Not providing DTP together with or after MV is associated with a 35 % reduction in overall mortality and 23% reduction in hospitalizations.

Objectives: To examine in a randomised study of 6000 children the effect of not administering DTP simultaneously with or after MV on

1. Overall child mortality

2. Hospitalization rates and major causes of hospitalization

3. The immunological profile after vaccination

4. Sex-differences in the above mentioned outcomes

Methods:

Surveillance system: BHP's demographic surveillance system in Bissau covers 6 districts with a population of 90,000; 3,500 children are born each year.

Hospitalizations: There is only one pediatric ward in Bissau and all hospitalizations are identified in the BHP register.

Vaccinations: Vaccinations are provided and registered at the 3 health centres in the study area.

Intervention: In this study 6000 children are randomised as they come to receive DTP3 or DTP booster with or after measles vaccination (MV) at the local health centres. Children will be randomised to DTP3+OPV3 and MV versus OPV3 and MV or DTP4+OPV4 versus OPV4 (booster doses).

Follow-up: The children will be followed until 4 years of age or end of study.

1. Adverse effects: In the first month after vaccination, 1000 children will be visited daily for three days and then weekly to register morbidity and consultations.

2. Hospitalizations: The children will be followed at the pediatric ward.

3. Mortality: Children will be followed by the routine surveillance system. Furthermore, all children will be visited yearly and finally when they reach four years of age. When a death is detected, a physician will conduct a verbal autopsy.

Sample size: With a total of 7500 person-years of follow-up, we will be able to document a 35% reduction in mortality and a 23% reduction in hospitalizations. A subgroup of children will be examined for possible differences in immunological profile after vaccination.

Ethical considerations: Herd immunity to pertussis should not be affected as, due to the intervention, more children is vaccinated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6534
• Est. completion date: December 2011
• Est. primary completion date: December 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 9 Months to 4 Years

Eligibility

Inclusion Criteria:

1. The child should be missing DTP3 or DTP4

2. The child should have received DTP2

3. The child should have received MV already or receive MV on the day of enrolment

Exclusion Criteria:

Normally applied contraindications for receiving vaccinations, including high fever

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Adverse Events
• Hospitalization
• Mortality

Intervention

Biological:
• DTP3/4+OPV+MV versus OPV+MV or DTP4+OPV4 versus OPV4
Trial of not providing 3. and/or 4. DTP together with or after MV at 9 to 18 month of age.

Locations

Country	Name	City	State
Guinea-Bissau	Bandim Health Project, Apartado 861	Bissau

Sponsors (3)

Lead Sponsor	Collaborator
Bandim Health Project	Aarhus University Hospital, Rigshospitalet, Denmark

Country where clinical trial is conducted

Guinea-Bissau, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mortality till 4 years of age		June 2011	Yes
Primary	Hospitalisations till 4 years of age		June 2011	Yes
Primary	Adverse events 1 month after intervention		December 2008	Yes
Secondary	Immunological responses		July 2008	Yes
Secondary	Morbidity		June 2011	Yes